Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | FAP | Q12884 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 2/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | CTSB | P07858 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | SDCBP | O00560 | 1/20 | 0.35 |
| ▸ | SDC2 | P34741 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31129093 | 0.97 | NPSR1 (0.38) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL29448573 | 0.96 | DPP4 (0.41) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL30668291 | 0.93 | DPP4 (0.39) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL30052907 | 0.93 | NPSR1 (0.41) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL34464920 | 0.87 | OPRD1 (0.38) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL27941881 | 0.87 | ALDH1A1 (0.41) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL29551131 | 0.85 | MME (0.41) | CTSDMME | |
| SCHEMBL31588230 | 0.84 | ALDH1A1 (0.43) | DPP4FAPDPP8DPP9DPP7 | |
| SCHEMBL29421862 | 0.84 | NPSR1 (0.39) | NPSR1SMN1; SMN2SDCBPSDC2ALDH1A1 | |
| SCHEMBL29926409 | 0.84 | NPSR1 (0.39) | NPSR1SMN1; SMN2CTSDMMESDCBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339152-B2 | Inhibitors | VIVORYON THERAPEUTICS N.V. | 2022-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339152-B2 | Inhibitors | GLUL, QPCT, GLS | DPP4 935/4885FAP 568/4885DPP8 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.